menu
    • menu

    Find Casdatifan manufacturers, exporters & distributors on PharmaCompass

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    Contact Supplier

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    0

    API Suppliers

    API Suppliers

    0

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    0

    NDC API

    NDC API

    0

    VMF

    NDC API

    0

    Listed Suppliers

    Other Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    0

    FDF Dossiers

    FDF Dossiers

    0

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    9DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 0

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Regulatory FDF Prices

    NA

    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    0

    API

    0

    FDF

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    4

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Schembl23846781, Ab521, Ex-a9762, Hy-159644, 2709069-30-5
    Molecular Formula
    C21H17F4NO3S
    Molecular Weight
    439.4  g/mol
    InChI Key
    KHBHHNNBNHHGPE-QCCZFBHPSA-N
    Casdatifan
    Casdatifan is an orally bioavailable allosteric inhibitor of hypoxia inducible factor (HIF)-2alpha, with potential antineoplastic activity. Upon oral administration, casdatifan targets and allosterically binds to a hydrophobic pocket on HIF-2alpha leading to a confirmational change that prevents HIF-2alpha heterodimerization with HIF-1beta and binding to the hypoxia response element (HRE) binding site on DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate tumor cell growth and survival. Blocking HIF-2alpha reduces the proliferation of HIF-2alpha-expressing tumor cells. HIF-2alpha, a heterodimeric transcription factor overexpressed under hypoxic conditions in many cancer cell types, promotes proliferation, progression and metastasis of tumors.
    1 2D Structure

    Casdatifan

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (5R,6S,8R)-3,5,6-trifluoro-8-[(1S,2R)-2-fluoro-1-hydroxy-7-methylsulfonyl-2,3-dihydro-1H-inden-4-yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile
    2.1.2 InChI
    InChI=1S/C21H17F4NO3S/c1-30(28,29)17-3-2-11(13-7-16(24)21(27)19(13)17)12-6-15(23)20(25)14-5-10(22)4-9(8-26)18(12)14/h2-5,12,15-16,20-21,27H,6-7H2,1H3/t12-,15+,16-,20-,21-/m1/s1
    2.1.3 InChI Key
    KHBHHNNBNHHGPE-QCCZFBHPSA-N
    2.2 Synonyms
    2.2.1 Depositor-Supplied Synonyms

    1. Schembl23846781

    2. Ab521

    3. Ex-a9762

    4. Hy-159644

    5. 2709069-30-5

    2.3 Create Date
    2021-11-10
    3 Chemical and Physical Properties
    Molecular Weight 439.4 g/mol
    Molecular Formula C21H17F4NO3S
    XLogP33
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count2
    Exact Mass Da
    Monoisotopic Mass Da
    Topological Polar Surface Area86.5
    Heavy Atom Count30
    Formal Charge0
    Complexity811
    Isotope Atom Count0
    Defined Atom Stereocenter Count5
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Arcus Retains Casdatifan Rights, Prices $150M Common Stock Offering

    Details:

    Gilead's window to exercise its option to casdatifan has expired and arcus retains rights to AB521 (casdatifan), a small-molecule inhibitor of HIF-2a.


    Lead Product(s): Casdatifan

    Therapeutic Area: Oncology Brand Name: AB521

    Study Phase: Phase IProduct Type: Other Small Molecule

    Sponsor: Gilead Sciences

    Deal Size: $1,600.0 million Upfront Cash: $375.0 million

    Deal Type: Collaboration February 18, 2025

    blank

    01

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Casdatifan

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Gilead Sciences

    Deal Size : $1,600.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Arcus Retains Casdatifan Rights, Prices $150M Common Stock Offering

    Details : Gilead's window to exercise its option to casdatifan has expired and arcus retains rights to AB521 (casdatifan), a small-molecule inhibitor of HIF-2a.

    Product Name : AB521

    Product Type : Other Small Molecule

    Upfront Cash : $375.0 million

    February 18, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

    Details:

    The net proceeds will support the the clinical development of AB521 (casdatifan), a small-molecule inhibitor of HIF-2a, for the treatment of clear cell renal cell carcinoma.


    Lead Product(s): Casdatifan

    Therapeutic Area: Oncology Brand Name: AB521

    Study Phase: Phase IProduct Type: Other Small Molecule

    Sponsor: Goldman Sachs & Co

    Deal Size: $150.0 million Upfront Cash: Undisclosed

    Deal Type: Public Offering February 18, 2025

    blank

    02

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Casdatifan

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Goldman Sachs & Co

    Deal Size : $150.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

    Details : The net proceeds will support the the clinical development of AB521 (casdatifan), a small-molecule inhibitor of HIF-2a, for the treatment of clear cell renal cell carcinoma.

    Product Name : AB521

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    February 18, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    New Data Shows Best-in-Class Potential for Casdatifan In Metastatic Kidney Cancer

    Details:

    AB521 (casdatifan) is a small-molecule inhibitor of HIF-2a, which is being evaluated for the treatment of clear cell renal cell carcinoma.


    Lead Product(s): Casdatifan,Cabozantinib

    Therapeutic Area: Oncology Brand Name: AB521

    Study Phase: Phase IProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 15, 2025

    blank

    03

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Casdatifan,Cabozantinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    New Data Shows Best-in-Class Potential for Casdatifan In Metastatic Kidney Cancer

    Details : AB521 (casdatifan) is a small-molecule inhibitor of HIF-2a, which is being evaluated for the treatment of clear cell renal cell carcinoma.

    Product Name : AB521

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 15, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Arcus Shows Promising Data for Casdatifan in Metastatic Kidney Cancer

    Details:

    AB521 (casdatifan) is a potential best-in-class HIF-2a inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of renal cell cancer.


    Lead Product(s): Casdatifan

    Therapeutic Area: Oncology Brand Name: AB521

    Study Phase: Phase IProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 24, 2024

    blank

    04

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Casdatifan

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Arcus Shows Promising Data for Casdatifan in Metastatic Kidney Cancer

    Details : AB521 (casdatifan) is a potential best-in-class HIF-2a inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of renal cell cancer.

    Product Name : AB521

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    October 24, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

    Details:

    The proceeds will be used to rapidly advance AB521 (casdatifan), its potential best-in-class HIF-2a inhibitor, for the treatment of renal cell cancer.


    Lead Product(s): Casdatifan,Encoberminogene Rezmadenovec

    Therapeutic Area: Oncology Brand Name: AB521

    Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

    Sponsor: Hercules Capital

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Financing August 27, 2024

    blank

    05

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Casdatifan,Encoberminogene Rezmadenovec

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Hercules Capital

    Deal Size : Undisclosed

    Deal Type : Financing

    DEALS_DEV arrow-down

    Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

    Details : The proceeds will be used to rapidly advance AB521 (casdatifan), its potential best-in-class HIF-2a inhibitor, for the treatment of renal cell cancer.

    Product Name : AB521

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    August 27, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Arcus Signs Trial Collaboration For Renal Cancer Therapy Combination

    Details:

    The collaboration aims to evaluate AB521 (casdatifan), an investigational HIF-2a inhibitor, in combination with volrustomig, AstraZeneca’s PD-1/CTLA-4 bispecific antibody, in patients with ccRCC.


    Lead Product(s): Casdatifan,Volrustomig

    Therapeutic Area: Oncology Brand Name: AB521

    Study Phase: PreclinicalProduct Type: Other Small Molecule

    Sponsor: AstraZeneca

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration February 10, 2024

    blank

    06

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Casdatifan,Volrustomig

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : AstraZeneca

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Arcus Signs Trial Collaboration For Renal Cancer Therapy Combination

    Details : The collaboration aims to evaluate AB521 (casdatifan), an investigational HIF-2a inhibitor, in combination with volrustomig, AstraZeneca’s PD-1/CTLA-4 bispecific antibody, in patients with ccRCC.

    Product Name : AB521

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    February 10, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal...

    Details:

    The companies will enter into a clinical trial collaboration evaluating XL092 (zanzalintinib), a tyrosine kinase inhibitor, in combination with AB521 in patients with advanced solid tumors including clear cell renal cell carcinoma.


    Lead Product(s): Encoberminogene Rezmadenovec,Casdatifan

    Therapeutic Area: Oncology Brand Name: XL092

    Study Phase: IND EnablingProduct Type: Cell and Gene therapy

    Sponsor: Arcus Biosciences

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration April 12, 2023

    blank

    07

    Exelixis

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed

    Exelixis

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Encoberminogene Rezmadenovec,Casdatifan

    Therapeutic Area : Oncology

    Highest Development Status : IND Enabling

    Partner/Sponsor/Collaborator : Arcus Biosciences

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in ...

    Details : The companies will enter into a clinical trial collaboration evaluating XL092 (zanzalintinib), a tyrosine kinase inhibitor, in combination with AB521 in patients with advanced solid tumors including clear cell renal cell carcinoma.

    Product Name : XL092

    Product Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    April 12, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Arcus Biosciences Presents Data from its Pipeline at Multiple Scientific Conferences

    Details:

    Initial pharmacokinetic /pharmacodynamic data for AB521, a Clinical-Stage, Potent, and Selective Hypoxia-Inducible Factor (HIF)-2α Inhibitor, in healthy volunteers, confirm its potential to have an improved clinical profile compared to that of only approved HIF-2a inhibitor.


    Lead Product(s): Casdatifan

    Therapeutic Area: Oncology Brand Name: AB521

    Study Phase: Phase IProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 03, 2022

    blank

    08

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Casdatifan

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Arcus Biosciences Presents Data from its Pipeline at Multiple Scientific Conferences

    Details : Initial pharmacokinetic /pharmacodynamic data for AB521, a Clinical-Stage, Potent, and Selective Hypoxia-Inducible Factor (HIF)-2α Inhibitor, in healthy volunteers, confirm its potential to have an improved clinical profile compared to that of only appr...

    Product Name : AB521

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    August 03, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Arcus Biosciences Presents Data from its Pipeline at Multiple Scientific Conferences

    Details:

    Preclinical research related to therapeutic opportunities to enhance anti-tumor immunity and new insights into the benet of dual A2a/A2b adenosine receptor antagonism, CD39 inhibition and HPK1 inhibition will be presented at the American Association for Cancer Research.


    Lead Product(s): Casdatifan

    Therapeutic Area: Oncology Brand Name: AB521

    Study Phase: Phase IProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 03, 2022

    blank

    09

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed

    Arcus Biosciences

    U.S.A
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Casdatifan

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Arcus Biosciences Presents Data from its Pipeline at Multiple Scientific Conferences

    Details : Preclinical research related to therapeutic opportunities to enhance anti-tumor immunity and new insights into the benet of dual A2a/A2b adenosine receptor antagonism, CD39 inhibition and HPK1 inhibition will be presented at the American Association for ...

    Product Name : AB521

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    August 03, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search